source
- Coherus Oncology cuts 30% of staff to focus on esophageal cancer comboCoherus Oncology announced another round of layoffs, reducing its workforce by about 30% as it narrows its development program. The cuts follow the presentation of phase 1b data on a combination o…
- AbCellera becomes latest biotech to abandon dream of developing OX40 drugAbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.Fierce Biotech · 6h ago↗ source